Bachem and Neuren Pharmaceuticals Limited today announced to continue their close collaboration on Glypromate® , Neuren's lead product currently under development for the prevention of cognitive impairment following major cardiac surgery. Recently the FDA has approved Neuren's investigational drug application (IND) and authorized the company to proceed with a phase III trial. This decision brings the partnership between Bachem and Neuren into a new dimension.

Press Release